QuidelOrtho was formed by the 2022 merger of Quidel and Ortho Clinical Diagnostics, creating a combined IVD company with revenues of approximately $3 billion in 2025. QuidelOrtho operates across rapid diagnostics, transfusion medicine, and clinical laboratory testing. The Sofia platform and BinaxNOW co-distributed products were deployed at unprecedented scale during COVID-19. Ortho's Vitros platform competes in the immunoassay and clinical chemistry core laboratory segment. QuidelOrtho's transfusion medicine business serves blood banks and hospital transfusion services with immunohematology analyzers and reagents. The company is navigating post-COVID volume normalization in rapid testing while investing in integration of the merged portfolios and expanding internationally.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Post-Merger Integration, Rapid Diagnostics Recovery, and Transfusion Medicine Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — Sofia, Vitros, Transfusion Medicine Platforms, and IP
• Latest Products and Services — Platform Launches, Multiplex Tests, and Innovation Pipeline
• M&A — Merger Integration Progress, Divestitures, and Partnerships 2023-2025
• Marketing Tactics — Rapid Diagnostics Channel Strategy and Transfusion Medicine Positioning
• Organization and Management — Leadership, Post-Merger Structure, and Workforce
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant developments 2024-2025
- Strategic recommendations
2. Strategic Directions
- Portfolio strategy and capital allocation priorities
- Technology investment focus areas
- Geographic expansion and market development
- Growth priorities through 2030
3. Financial Performance
- Revenue and revenue growth 2023-2025
- Revenue by segment 2023-2025
- Revenue by geography 2023-2025
- Operating income, margins, and EBITDA 2023-2025
- R&D investment 2023-2025
4. SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
5. Technological Know-How
- Core technology capabilities and IP portfolio
- AI and digital diagnostics investments
- Key platform systems and technology milestones
6. Latest Products and Services
- Recent product and platform launches 2023-2025
- Key analyzer and reagent portfolio
- Innovation pipeline and development programs
7. M&A
- Acquisitions, divestitures, and partnerships 2023-2025
8. Marketing Tactics
- Segment and channel positioning
- Reagent rental and placement strategy
- Key account and GPO strategy
9. Organization and Management
- Leadership and executive team
- Organizational structure and key changes
- Workforce size and developments
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. QuidelOrtho — Key Financial Metrics Summary 2023-2025
Table 2. QuidelOrtho — Revenue by Segment 2023-2025
Table 3. QuidelOrtho — Revenue by Geography 2023-2025
Table 4. QuidelOrtho — R&D Investment 2023-2025
Table 5. QuidelOrtho — SWOT Analysis
Table 6. QuidelOrtho — Core Technology Capabilities and Key Platforms
Table 7. QuidelOrtho — Key Analyzers and Reagent Portfolio
Table 8. QuidelOrtho — M&A Activity Summary 2023-2025
Table 9. QuidelOrtho — Key Management and Leadership
Table 10. QuidelOrtho — Strategic Priorities 2025-2030
